Threshold Pharmaceuticals (THLD) Surges On Positive Pancreatic Cancer Trial Data
Tweet Send to a FriendGet Alerts THLD Hot Sheet
Trade THLD Now!
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) is surging over 60 percent in pre-open trading Tuesday following positive Phase 2b clinical trial results of TH-302 in pancreatic cancer.
The company said the primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). Also, the combination therapy was well tolerated with a safety profile consistent with prior studies.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company said the primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). Also, the combination therapy was well tolerated with a safety profile consistent with prior studies.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Viropharma, Inc. (VPHM) Said to Attract Acquisition Interest - Reuters
- AMD (AMD) on Watch after Executive Shift at Largest Customer (HP)
- Orchard Supply (OSH) Sees Complete Loss of Equityholder Investment in Ch. 11 Proceedings
Create E-mail Alert Related Categories
FDA, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
